Grants per year
Personal profile
Research Interests
Development of novel patient derived orthotopic xenograft mouse models, understand tumor biology and identify new diagnostic and/or therapeutic targets, perform comprehensive preclinical drug testing to establish preclinical rational for the initiation of clinical trials.
Nonn.
Training Experience
| 1990 | Residency, Suzhou Medical College/Soochow University, PR.China |
| 1992 | Fellowship, Suzhou Medical College/Soochow University, PR.China |
| 2001 | Postdoctoral Fellowship, Baylor College Of Medicine |
Education/Academic qualification
PhD, Suzhou Medical College/Soochow University
… → 1993
MD, Suzhou Medical College/Soochow University
… → 1985
Fingerprint
Dive into the research topics where Xiaonan Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 2 Active
-
Corrigendum to “Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors” [Cancer Lett. 493 (2020) 197–206] (Cancer Letters (2020) 493 (197–206), (S0304383520304493), (10.1016/j.canlet.2020.08.035))
Qi, L., Kogiso, M., Du, Y., Zhang, H., Braun, F. K., Huang, Y., Teo, W. Y., Lindsay, H., Zhao, S., Baxter, P., Zhao, X., Yu, L., Liu, Z., Zhang, X., Su, J., Adesina, A., Yang, J., Chintagumpala, M., Perlaky, L., Tsz-Kwong Man, C. & 2 others, , Mar 1 2021, In: Cancer Letters. 500, p. 294 1 p.Research output: Contribution to journal › Comment/debate › peer-review
-
CRISPR editing of the GLI1 first intron abrogates GLI1 expression and differentially alters lineage commitment
Galat, Y., Gu, H., Perepitchka, M., Taylor, R., Yoon, J. W., Glukhova, X. A., Li, X. N., Beletsky, I. P., Walterhouse, D. O., Galat, V. & Iannaccone, P. M., May 2021, In: Stem Cells. 39, 5, p. 564-580 17 p.Research output: Contribution to journal › Article › peer-review
Open Access -
International consensus on minimum preclinical testing requirements for the development of innovative therapies for children and adolescents with cancer
Vassal, G., Houghton, P. J., Pfister, S. M., Smith, M. A., Caron, H. N., Li, X. N., Shields, D. J., Witt, O., Molenaar, J. J., Colombetti, S., Schuler, J. & Stancato, L. F., Aug 2021, In: Molecular cancer therapeutics. 20, 8, p. 1462-1468 7 p.Research output: Contribution to journal › Article › peer-review
-
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing
Elghetany, M. T., Ho, J. M., Shi-Qi, L. H., Karthik, S., Su, J. M. F., Lin, Q., Du, Y. C., Shen, J., Chow, W. Y., Lau, C. C., Adesina, A., Major, A., Erdreich-Epstein, A., Hui, K. M., Li, X. N. & Teo, W. Y., Dec 2021, In: Scientific reports. 11, 1, 11580.Research output: Contribution to journal › Article › peer-review
Open Access -
REST promotes ETS1-dependent vascular growth in medulloblastoma
Shaik, S., Maegawa, S., Haltom, A. R., Wang, F., Xiao, X., Dobson, T., Sharma, A., Yang, Y., Swaminathan, J., Kundra, V., Li, X. N., Schadler, K., Harmanci, A., Xu, L. & Gopalakrishnan, V., May 2021, In: Molecular oncology. 15, 5, p. 1486-1506 21 p.Research output: Contribution to journal › Article › peer-review
Open Access